TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06354543

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study: NCT02124850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT04635735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
Study: NCT00090285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
Study: NCT06354543

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study: NCT04128592

Intervention type: DEVICE
Group type: OTHER
Intervention: diagnosing noisy breathing in infants and toddlers
Description: breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
Study: NCT00975754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort pMDI HFA
Description: Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide pMDI HFA
Description: Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide pMDI HFA
Description: Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Repulses
Description: Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Turbohaler
Description: Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
Study: NCT04906538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: all- inside anterior cruciate ligament reconstruction
Description: all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: all- inside anterior cruciate ligament reconstruction
Description: all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
Study: NCT01458340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily
Study: NCT02499965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethyl Chloride Topical Aerosol Anesthetic
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nature's Tears Sterile Water
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Study: NCT02241018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcineurin inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcineurin inhibitors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study: NCT03295422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF ablation PVI alone
Description: A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
Study: NCT03203343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation - PIRS
Description: Operation by its known design for PIRS group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation - MARCY
Description: Operation by its known design for MARCY group
Study: NCT04622228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT03295422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF ablation PVI plus LPAW
Description: A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
Study: NCT02094105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy examination with iodine staining
Description: Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
Study: NCT04250805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
Study: NCT04088318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OQL011
Description: OQL011 is an ointment containing active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OQL011
Description: OQL011 is an ointment containing active ingredient.
Study: NCT04250805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
Study: NCT04622228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT02842853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT04622228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT02842853

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT04622228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy (TRT)
Description: Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
Study: NCT02762851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 ml dose injected intramuscularly
Study: NCT03334214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS DGAT2Rx
Description: Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
Study: NCT06354543

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study: NCT02762851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inactivated trivalent influenza vaccine
Description: 0.5 ml dose injected intramuscularly
Study: NCT03922490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems Device PLUS debridement
Description: Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
Study: NCT04088318

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle Ointment
Description: Vehicle ointment is an ointment containing no active ingredient.
Study: NCT04369924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unidimensional Measurement-Based Care
Description: Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
Study: NCT03922490

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement only
Description: Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
Study: NCT04369924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Measurement-Based Care
Description: Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
Study: NCT06354543

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study: NCT03334214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9%
Study: NCT03713255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB group
Description: Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTP block group
Description: Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
Study: NCT03025087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine
Study: NCT04618887

Intervention type: PROCEDURE
Intervention: pallidotomy
Description: deep brain nuclei lesion of GPi
Study: NCT03025087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will be getting hydroxychloroquine
Study: NCT00635648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
Study: NCT01585792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT06354543

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components

Intervention type: DEVICE
Intervention: Cemented joint arthroplasty
Description: Joint replacement with cemented prosthetic components
Study: NCT01038895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: tablet; 10 mg; od; 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: tablet; 300 mg; od; 3 months
Study: NCT02722603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: 75 mg/ml gabapentin syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: 100 mg/ml tramadol oral drops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo tramadol
Description: placebo tramadol oral drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gabapentin
Description: placebo gabapentin syrup
Study: NCT01029483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
Study: NCT04618887

Intervention type: PROCEDURE
Intervention: deep brain stimulation
Description: deep brain stimulation of GPi
Study: NCT01455129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily, inhaled by HandiHaler
Study: NCT03535571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon Protein Hydrolysate
Description: 4g of salmon protein hydrolysate per serving.
Study: NCT03447197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The use of extracorporeal circulation
Description: The use or not of extracorporeal circulation during the coronary artery bypass procedure.
Study: NCT00558129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-STOP®
Description: Surgical implantation of X-STOP IPD device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy
Description: Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
Study: NCT01307605

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
Study: NCT03713255

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
Study: NCT03624998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and physiatric testing
Description: Neuropsychological test battery and physiatric tests
Study: NCT00003820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Study: NCT01982110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based smoking cessation
Description: Mindfulness based interventions are provided via a mobile phone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation intervention
Description: Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
Study: NCT03528252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written advice LDL Cholesterol
Description: One A4 paper with written information on both sides

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Written advice Triglycerides
Description: One A4 paper with written information on both sides
Study: NCT01307605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide
Description: Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
Study: NCT02297217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Taxol (paclitaxel)
Description: Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Description: Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
Study: NCT04174157

Intervention type: OTHER
Intervention: Prospective observational registry
Description: This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
Study: NCT01029483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-carbohydrate ad libitum intervention
Description: Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet-energy matched intervention
Description: Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
Study: NCT03437733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter